Brokerages Expect Ovid Therapeutics Inc (OVID) Will Announce Earnings of -$0.59 Per Share

Wall Street analysts predict that Ovid Therapeutics Inc (NASDAQ:OVID) will announce ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Ovid Therapeutics’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.55). Ovid Therapeutics reported earnings of ($0.38) per share during the same quarter last year, which indicates a negative year over year growth rate of 55.3%. The firm is scheduled to report its next earnings report on Thursday, November 8th.

On average, analysts expect that Ovid Therapeutics will report full-year earnings of ($2.26) per share for the current financial year, with EPS estimates ranging from ($2.36) to ($2.15). For the next financial year, analysts forecast that the firm will report earnings of ($2.54) per share, with EPS estimates ranging from ($2.79) to ($2.25). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Ovid Therapeutics.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.07.

Several equities analysts recently commented on OVID shares. Zacks Investment Research upgraded shares of Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a report on Tuesday, September 4th. ValuEngine downgraded shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. Piper Jaffray Companies set a $20.00 price target on shares of Ovid Therapeutics and gave the company a “buy” rating in a report on Monday, August 6th. Finally, BidaskClub downgraded shares of Ovid Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 27th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $18.08.

Shares of NASDAQ:OVID opened at $5.68 on Friday. The stock has a market cap of $139.66 million, a P/E ratio of -1.70 and a beta of 1.29. Ovid Therapeutics has a 12 month low of $5.20 and a 12 month high of $12.44.

In other news, Director Douglas E. Williams purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were bought at an average cost of $6.49 per share, for a total transaction of $32,450.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 43.90% of the company’s stock.

A number of large investors have recently modified their holdings of OVID. Schwab Charles Investment Management Inc. grew its stake in Ovid Therapeutics by 67.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 34,295 shares of the company’s stock worth $243,000 after acquiring an additional 13,785 shares in the last quarter. Northern Trust Corp grew its stake in Ovid Therapeutics by 81.7% in the 1st quarter. Northern Trust Corp now owns 118,430 shares of the company’s stock worth $837,000 after acquiring an additional 53,264 shares in the last quarter. BlackRock Inc. grew its stake in Ovid Therapeutics by 27.8% in the 1st quarter. BlackRock Inc. now owns 1,358,459 shares of the company’s stock worth $9,606,000 after acquiring an additional 295,247 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Ovid Therapeutics by 482.8% in the 1st quarter. JPMorgan Chase & Co. now owns 33,006 shares of the company’s stock worth $233,000 after acquiring an additional 27,343 shares in the last quarter. Finally, DRW Securities LLC bought a new position in Ovid Therapeutics in the 1st quarter worth about $108,000. Institutional investors own 31.06% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

See Also: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Ovid Therapeutics (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply